Accurate prediction of response to immune checkpoint blockade (ICB) and simultaneous development of new efficacious ICB strategy are unmet needs for cancer immunotherapy 1-5 .
Main Text
Characteristics of TIL exhaustion are generally considered as low effector function, decreased proliferation, and diminished cytokine production [13] [14] [15] [16] . However, the challenges in understanding the key role of TIL exhaustion, especially in determining responses to ICBs, come with the identification of appropriate exhaustion biomarker or criterion. At the singlecell level, the quantitative exhaustion criterion is required to be able to demonstrate fundamentally distinct types of T cell functions represented by various functional molecules, such as, surface exhaustion markers (PD-1, CTLA-4, LAG3, TIM3, VISTA, TIGIT, etc) [22] [23] [24] [25] [26] , related transcriptional factors (EOMES, T-BET, PRDM1, etc) 15 , effector molecules (IFNG, GZMB, GZMA, PRF1, FASLG) 27 , and tumor-specificity markers (CD39 and CD103) 11, 12 .
The developed D value as such a quantitative exhaustion criterion models TILs within a highdimensional expression space defined by a number of exhaustion related markers (Online Methods, Extended Data Fig. 1, Supplementary Methods) . To predict response to ICB, we used two single-cell mass cytometry (CyTOF) datasets 17 , including 11 specimens from 7 melanoma patients received the ICBs of aPD-1, aCTLA-4, or aPD-1+aCTLA-4 and another 34 mouse specimens from melanoma mouse tumors received the ICBs of aPD-1 or aCTLA-4 (Online Methods, Extended Data Fig. 2-3, Supplementary Table 1-2) . D-values for the tumors were identified from a 11-dimensional expression space (immune checkpoints or ICs:
PD-1, CTLA-4, LAG3, and TIM3, other relevant markers: KLRG1, Blimp1, BCL6, Ki-67, and CD127, and the related transcriptional factors or TFs: EOMES and T-bet). The proportion of the PF single cells in all TILs is 18%±5% ( Fig. 1a, Supplementary Table 3 ). We identified that the exhausted CD8 + TILs of the non-responders have significantly higher D-values than those of responders (P < 10 -16 , Mann-Whitney U test), refer to Fig. 1b,e . The proportion of D-high TILs in non-responders is significantly higher than that in responders (P < 10 -15 , Fisher's exact test, Fig. 1c-d) . By analyzing the contributions (DEi) of the exhaustion markers to D values, we observed significant contributions from PD-1, CTLA-4, and LAG3 to high D values in nonresponder ( Fig. 1g , P < 10 -16 , Mann-Whitney U test). Thus, D value predicts clinical response to ICBs in human tumors accurately, that is, AUC=100% (Online Methods, Fig. 1f) . Similarly, D value predicts ICB responses of mouse tumors at the accuracy of AUC=83% (Extended Data Fig. 4c ). More importantly, the prediction accuracy is not affected by the number of exhaustion markers used in the model (Extended Data Fig. 9 , an example with 6 markers). Next, to explicit fundamentally different T cell functionalities as well as phenotypic gene signatures underlying D-high and D-low TILs, we analyzed another single-cell RNA-seq (scRNA-seq) dataset 28 of 1,233 TILs pooled from 8 melanoma patients (Online Methods, Extended Data Fig. 5-6 ). Most of these patients received the ICBs of aPD-1, aCTLA-4, or aPD-1+aCTLA-4 ( Supplementary Table 4 ). We used LAG3, TIGIT, HAVCR2 (TIM3), PDCD1 (PD-1), CTLA-4, IRF4, EOMES, and CD160, as exhaustion markers ( Fig. 2a , Extended Data Fig. 6, Supplementary Text) . We divided the PF TILs into four categories: D Extremely-high (top 1%), UQ_90 (D-high, top 2%-10%), UQ_75 (D-high, upper quartile excluded top 10%), and D-low (lower 75%), ref to Fig. 2a , Supplementary Table 5 . D-high and D-low as well as non-PF TILs (TILs excluded by PFs) show distinct activation of T cell signaling pathways and functions, including cytotoxic T cell signaling, CD28 signaling, PCKe signaling, cytokine-related gene signature, and exhaustion gene signature (Online Methods, Fig. 7 ). It seems that non-PF TILs are resting T cells displaying neither exhaustion nor cytotoxicity 27 , but enriched with a central memory signature including markedly increased expression of IL-7R, LEF1, SELL, CCR7, and VAX2 ( Fig. 2d) . Most importantly, non-PF TILs have significantly low tumor-specificity described by CD39 low/neg CD103 low/neg11,12 ( Fig. 2e ). This explains why we observed a large portion of non-PF TILs that seem to be irrelevant to treatment response because they are tumor-infiltrating bystander T cells.
Fig.2b-c, Extended Data

D-high and D-low TILs show fundamentally distinct signaling signatures. The TILs with D
Extremely-high display highest exhaustion and inactivation of both cytotoxicity and effector functions, together with decreased IFN-g production. With the decrease of D values which comes with downregulation of T cell exhaustion, the tumor-specific TILs with UQ_90 and UQ_75 demonstrate a gradually upregulated activation of effector T cell signatures, including cytotoxicity and T cell activation through TCR, PCKe and CD28 signals. In addition, the lessexhausted D-low TILs are tumor-specific cytotoxic effectors ( Fig. 2b-c) . Of note, the TILs with D-high are terminally differentiated effector (KLRD1 and ZEB2), with the high expression of T cell exhaustion (PD-1, LAG3, CTLA-4, TIM3, etc.) and tumor specificity markers (CD39 and CD103), but inactivated in prosurvival and long-lived gene signature (e.g., IL7R, LEF1, and SELL), proliferation (Ki-67), cytokine production (INFG, IL2, and TNF), and cytotoxicity (GZMA, GZMB, PRF1, and FASLG). The result from scRNA-seq analysis is highly consistent with the observed D-high TILs in non-responders identified from the CyTOF data. The TILs with high D values possess their unique exhaustion accompanied by high tumor-specificity and irreversible T-cell dysfunction (at least not by aPD-1/aCTLA4), which lead to the therapy resistance of the present ICBs in non-responders.
To determine whether the good outcome of the clinical responders is determined by specific exhaustion markers after receiving aPD-1, aCTLA-4, or aPD-1+aCTLA-4, we further defined the contribution ratio of each marker to the D value, that is, DEi/Ei, the ratio between increased expression level of each marker in a PF single cell compared to its non-PF baseline single cells (DEi) and the expression level of this marker in this PF single cell (Ei), see Online Methods, Extended Data Fig. 1 . Comparison of the contribution ratios of the exhaustion markers between responders and non-responders revealed that LAG3 has low contribution to D values in most PF TILs of responders ( Fig. 3a,c) . In other words, LAG3 does not show high expression levels in most PF TILs of responders. Analysis of the LAG3-low PF TILs by CD45RA, CD45RO, and CD127, revealed that these exhausted TILs show high effector but low memory function in the responders (Extended Data Fig. 8a ). To predict efficacious ICB combinations based on the contribution ratios of the exhaustion markers, including PD-1, CTLA-4, LAG3, and TIM3, we defined an in-silico exhaustion value for each tumor by using the burst levels of DE/E and D values of the PF TILs (exhausted TILs), refer to Online Methods. The in-silico TIL exhaustion value, Ex, represents to what extent the selected exhaustion markers included in a new ICB combination have burst expression in D-high TILs after receiving aPD-1, aCTLA-4, or aPD-1+aCTLA-4 (Online Methods). By associating the predicted Ex values of tumors with their clinical responses to ICBs, we identified the important roles of LAG3 in developing alternative ICB strategies, e.g., aLAG3+aPD-1+aCTLA-4 ( Fig.3b ). The role of LAG3 in ICB combinations remains to be identified 29, 30 though the combination of aLAG3 with aPD-1 or aCTLA-4 in ongoing clinical trials (NCT01968109). Importantly, we validated the superiority of the new ICB combination, aLAG3+aPD-1+aCTLA-4, in eradicating established mice tumors and prolonging mice survival, compared to aPD-1+aCTLA-4 and other ICB combinations with aPD-1+aCTLA-4. By in vitro experiments, we firstly observed significantly upregulated expression levels of PD-1, CTLA-4, and LAG3 in the activated CD8 + T cells after co-culture with MC38-OVA tumor cells ( Fig.   4a , P < 10 -16 , Two-sample Kolmogorov-Smirnov test), but no changes in the presence of aPD-1 + aCTLA-4 or isotype-matched antibody (IgG), see Fig. 4b . We next tested the antitumor capacity of aLAG3+aPD-1+aCTLA-4, compared to PBS, IgG, aLAG3, aPD-1+aCTLA-4, in the CT26 mouse model that shows resistance to most known ICBs. As expected, PBS, IgG, aLAG3, aPD-1+aCTLA-4 show resistance although moderate improvement for aPD-1+aCTLA-4 ( Fig. 4c) . Strikingly, aLAG3+aPD-1+aCTLA-4 eradicated the large established tumors with long-term tumor-free survival ( Fig. 4c-e) .
Additionally, we also tested the antitumor ability of other ICB combinations, e.g., aTIM3+aPD-1+aCTLA-4 and aTIGIT+aPD-1+aCTLA-4, but no better improvement than aPD-1+aCTLA-4 treatment was observed (Extended Data Fig. 10a ). Mechanistically, aLAG3+aPD-1+aCTLA-4 leads to markedly increased tumor-infiltrating CD4 + and CD8 + T cells, compared to other treatments (Fig. 4f) . The statistical analysis by normalizing T cell number to per mg tumor demonstrates a dramatical increase of CD4 + and CD8 + T cells in the treatment by aLAG3+aPD-1+aCTLA-4 ( Fig. 4g) . Lastly, we implemented high-dimensional single-cell analysis by CyTOF on the tumors from the 5 treatment groups (Online Methods, Extended Data Fig. 10b ). Notably, the T cell populations from aLAG3+aPD-1+aCTLA-4
show extremely high expression levels of GzmB (4 times higher than aPD-1+aCTLA-4 and ~300 times higher than other treatments) and high tumor specificity, refer to Fig. 4h and 
Reagent
IgG control, aPD-1 (clone RMP1-14), aCTLA-4 (clone UC10-4F10-11), aLAG3 (clone C9B7W), aLAG3 (clone RMT3-23), and aTIGIT (clone 1G9) were purchased from BioXcell.
Human IL-2 was purchased from R&D Systems.
In vitro cell coculture
Naïve CD8 + T cells were purified from the spleens of OT-I mice by isolation kit (STEMCELL Technologies, Cat#19858) according to the manufacturer's protocol. OT-I-specific naïve CD8 T cells were cultured for 5 days with Dynabeads (cat#11452D, Thermo Fisher) in the presence of hIL-2(100 U/ml). After cultured for 5 days, the activated CD8 T cells were cocultured with 0.3×10 6 MC38-OVA cells plus control IgG or PBS or MC38-OVA cells plus aPD-1 and aCTLA-4 for 48 hours in the presence of IL-2 (50 U/mL).
Flow cytometry
FITC-, PE-or eFluor-conjugated mAbs (1:100 dilution) were used for staining after Fc blocking. Samples were acquired with Fortessa flow cytometer and data were analyzed with Flowjo software.
In vivo murine tumor experiments
BALB/c mice were inoculated subcutaneously (s.c.) at the right flank with 1×10 6 CT26 tumor cells in 0.1 mL of PBS. Treatment was started at day 7 when tumors area reached about 50 mm 2 (~8×7 mm). IgG control (100 µg, ~4 mg/kg), aPD-1 (100 µg, 4 mg/kg), aCTLA-4 (100 µg, 4 mg/kg), aLAG3 (100 µg, 4 mg/kg), aTIM3 (100 µg, 4 mg/kg), and aTIGIT (100 µg, 4 mg/kg), alone or in combination, were intraperitoneal (i.p.) injection on days 7 and 10 after tumor injection. Tumors were measured by caliper and tumor area were calculated as width × length. At the time of sacrifice for analysis, mice were euthanized using CO2 and subsequent cervical dislocation.
Mass cytometry antibodies
Metal conjugated antibodies were purchased from Fluidigm or conjugated to unlabeled antibodies in our lab. All non-platinum conjugations were performed using Maxpar Antibody Table 2 . The tumor volumes of the 34 mice after ICB therapy and the 18 control mice were derived. 13 Human melanoma scRNA-seq data include 19 tumor tissue specimens from 19 patients, in which 14 8 patients (n = 8) have more than 50 CD8 + TILs. These patients received αPD-1, αCTLA-4, or 15 αPD-1+αCTLA-4, Supplementary Table 4 . 16 The CyTOF data were bead-normalized and debarcoded mass cytometry. We applied Flow-17 SOM analysis to the raw data. The expression values were arcsinh transformed by the antibod- 18 ies for transformation ( Supplementary Tables 5-6 ). In order to apply HD-scMed to the tumors 19 and compare the tumors, we further applied upper-quartile normalization to the processed CyTOF 20 data. The CD8 + TILs were identified by consensus clustering of the antibodies for cell linage 21 
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( Supplementary Tables 5-6 , Extended Data Figs. 2-3) . The scRNA-seq data were the processed data that were normalized by house-keeping genes as described in ref. 23 High-dimensional single-cell based computational method (HD-scMed). 24 HD-scMed identifies exhausted TILs from a high-dimensional expression space defined by a va- 25 riety of exhaustion markers, including immune checkpoints and related transcriptional factors 26 (Extended Data Fig. 1 ). The number of exhaustion markers included in HD-scMed is determined 27 by the available antibodies in the CyTOF data and the functionality of diverse exhaustion mark- 
. . , c m (x)] ≤ 0} is called as a fea-37 sible set, containing the set of decision vectors x that satisfies the constraints e(x) ≤ 0. 
where y a and y b are the marker expression levels of the candidate TILs, a and b. If we have y a > y b , we need the follows. Perato front or PF.
67
In this paper, Perato front or PF is used to identify exhausted TILs in the high-dimensional expres- Thus, the PF TILs were defined as those TILs with strength score higher than zero and fitness score 98 that equals to 0, i.e.,
99
A TIL a is a PF TIL ⇔ S(a) > 0 and F (a) = 0 (4) D value. where Ω ⊆ Ω satisfying that
Precisely, D value for the TIL a is called D a ,
where D a,b is defined by the ∆E i of the exhaustion markers in the high-dimensional expression
In the analysis of human melanoma CyTOF data (Fig. 1) , the PF TILs were classified into D is defined as follows.
142
where 
where a is the number of upregulated genes, b is the number of downregulated genes, and n is the 160 total gene number in the pathway or gene signature.
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Statistical analyses.
162
We have implemented the statistical analyses by R. 
